Every 8-K that Trulieve Cannabis Corp. (TRLV) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TRLV and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRLV filings page.
Trulieve Cannabis Corp. has changed its corporate jurisdiction from the Province of British Columbia, Canada, to the State of Delaware through a domestication effective August 11, 2026. A certificate of domestication and a new certificate of incorporation were filed with the Delaware Secretary of State, implementing a court-approved Plan of Arrangement previously approved by shareholders.
On the effective date, each previously authorized, issued and outstanding British Columbia subordinate voting share was automatically exchanged for one Class A subordinate voting common share, and each British Columbia multiple voting share was exchanged for one Class B multiple voting common share, all with a par value of $0.0001 per share. Outstanding stock options, RSUs and PSUs tied to the former British Columbia subordinate voting shares were converted into awards over the new subordinate voting shares on equivalent terms.
The rights of security holders are now governed by the new Delaware certificate of incorporation, bylaws and the Delaware General Corporation Law, which differ from the prior British Columbia regime as described in the company’s proxy materials. The company has also entered, or will enter, into indemnification agreements with its directors and executive officers, providing indemnification and advancement of expenses in connection with their service.
Trulieve Cannabis reported second-quarter 2026 revenue of $271 million, down 10% from a year earlier, with 94% from retail and medical-only revenue of $222 million. Gross profit was $162 million, a 60% margin.
GAAP net loss attributable to common shareholders was $406 million or $(2.10) per share, driven by a $403.3 million loss on deconsolidating its mixed medical and adult-use Harvest operations, which were restructured to enable listing on the NYSE. Adjusted net income was $20.4 million ($0.11 per share) and adjusted EBITDA $98 million, a 36% margin. Cash flow from operations reached $108.8 million year-to-date, free cash flow $74.4 million, and cash was $325.4 million against $289 million of debt at 9.6% interest.
Following federal rescheduling of state-licensed medical marijuana to Schedule III, Trulieve registered all medical facilities with the DEA, now operates 207 DEA-registered medical dispensaries and 3.5 million square feet of capacity, and retains a 90% economic interest in Harvest. The company also authorized a share repurchase program up to the lesser of $50 million or 8,495,038 subordinate voting shares and now expects at least $225 million of 2026 operating cash flow and up to $95 million of 2026 capital expenditures.
Trulieve Cannabis Corp. reported the results of a special meeting of shareholders held on August 5, 2026. Shareholders were asked to vote on a proposal regarding Delaware domestication of the company and on a separate adjournment proposal, both of which had been described in a definitive proxy statement filed on June 25, 2026.
The Delaware domestication proposal received 71,756,586 votes for, 383,078 votes against, and 50,472 abstentions. The adjournment proposal received 71,718,977 votes for, 358,779 votes against, and 112,380 abstentions.
Trulieve Cannabis Corp. reported a leadership change in its finance organization. As of June 30, 2026, the company eliminated the stand-alone role of Chief Accounting Officer and terminated Brett Walsh’s employment in that position without cause.
At the same time, Trulieve designated its Chief Financial Officer, Jan Reese, as principal accounting officer, consolidating the top finance and accounting responsibilities under one executive. The company noted that Reese will not receive any change or increase in compensation for assuming the additional accounting officer duties.